Given in vitro and in vivo evidence that estrogen and APOE may act synergistically [41]–[43], and evidence of sex differences in the association between APOE-ε4 carrier status and AD biomarkers [44]–[48], we were motivated to measure the impact of hormone replacement therapy on telomere dynamics as a function of APOE status. Here, APOE is linked to Alzheimer disease.